Nexalin Technology, Inc. (NXL)
About Nexalin Technology, Inc.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the US and China, with China generating the maximum sales.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $301.6K
- Net income
- -$8.2M
- Total assets
- $4.6M
- Market cap
- $10.6M
- Gross margin
- 79.7%
- Operating margin
- -2781.7%
- Net margin
- -2725.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $301.6K
- Cost of revenue
- $61.4K
- Gross profit
- $240.3K
- Operating expenses
- $8.6M
- Operating income
- -$8.4M
- Net income
- -$8.2M
- EPS (basic)
- $-0.50
- EPS (diluted)
- $-0.50
Balance sheet
- Total assets
- $4.6M
- Current assets
- $4.3M
- Total liabilities
- $887.3K
- Current liabilities
- $887.3K
- Shareholders’ equity
- $3.7M
Cash flow
- Operating cash flow
- -$5.0M
- Investing cash flow
- -$132.0K
- Financing cash flow
- $5.2M
- Net cash flow
- $80.3K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $10.6M
- EPS (diluted)
- $-0.5
- Dividend yield
- 500.0%
- Shares outstanding
- 42.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 16, 2022
Nexalin Technology, Inc. (NXL) Stock Price
- Reported a net loss of $8.2M in FY2025.
- Revenue declined 77% from FY2022 to FY2025.
- Gross margin of 79.7%, net margin -2725.8%.
- Trading 87% below its 52-week high.
- Pays a dividend yielding about 500.0% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Nexalin Technology, Inc..
Write a review
News about Nexalin Technology, Inc.
News & sentiment via Polygon.io
Nexalin Technology, Inc.: frequently asked questions
Is Nexalin Technology, Inc. an American company?
Nexalin Technology, Inc. is a US-based company headquartered in Houston, Texas, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Nexalin Technology, Inc. headquartered?
Nexalin Technology, Inc. is headquartered in Houston, Texas, United States.
Is Nexalin Technology, Inc. publicly traded?
Yes — Nexalin Technology, Inc. is a publicly traded company. Its stock trades under the ticker symbol NXL on the NASDAQ.
What does Nexalin Technology, Inc. do?
Nexalin Technology, Inc. is an American Medical Devices company in the Health & Beauty sector.
